journal of reports in cancer and treatment
HG Amin Sarkhosh, Rahim Ahmadi. Apatinib improved median PFS and OS versus placebo in Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma in the third line and beyond[152]. Int J Cancer. The landmark ToGA trial revealed that trastuzumab plus chemotherapy significantly improved the overall survival of patients with advanced GC [14], especially for patients with HER2 positivity, who were identified as having HER2 immunohistochemistry (IHC) scores of 2+and fluorescence in situ hybridization (FISH)-positive or HER2 IHC 3+based on a post-hoc exploratory analysis [92]. Nat Rev Clin Oncol. Sampera et al. 2016;21(9):108590. To address these challenges, optimization of the toxin, linker and toxicity of ADCs is essential, along with the development of ADC-combination therapies to improve efficacy. PubMed As mentioned above, in the CheckMate-649 study, the combination of anti-PD-1 and anti-CTLA-4 agents (nivolumab plus ipilimumab) failed to improve treatment outcomes compared to traditional chemotherapy [57]. Targeted therapies, including anti-HER2, anti-angiogenesis, and other biomarker-directed therapies, have demonstrated promising efficacy in treating GC, with significant benefits observed in biomarker-enriched patients (Table 3). Aortic aneurysm with thrombosis, as well as peripheral vascular thrombosis with aortic aneurysm in some cases, are a contraindication to chemotherapy for cancer patients. Cancer Discov. Article Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. On the 7th day after the surgery, the patient was discharged home in satisfactory condition. Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs) with several new agents approved for use. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTANa randomized, phase III study. More than 783,000 people die of stomach cancer worldwide each year [1]. Gastric cancer. CAS Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiCa randomized phase III trial. Ann Oncol. CAS Cancer treatment and survivorship statistics, 2022 - PubMed Noh SH, et al. Oesophageal carcinoma. ICI combined with other anti-immunosuppressive factor agents, such as anti-transforming growth factor- (TGF-), is also being investigated in clinical trials (NCT04856774). Invest New Drugs. After the control x-ray on the 5th day after the surgery, the patient began to eat through the mouth in full. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: a randomized, phase 3 trial. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, Kohler BA, Jemal A. Epub 2012 Jun 14. Luo H, et al. Cancer Commun (Lond). Department of Radiology, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Miami Sylvester Comprehensive Cancer Center, Late-Stage Development, Oncology R&D AstraZeneca. Hofheinz RD, et al. Emerging immunological strategies: recent advances and future directions. However, the reliable cut-off value to predict the benefit of immunotherapy is needed to be determined. Lordick F, et al. Goetze TO, et al. statement and Thus, one of the major challenges in systemic treatments for GC is overcoming resistance to ICI therapy. 2019;30(9):147986. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Article Gut. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. Cancer Reports is an international, peer-reviewed, open access journal publishing basic, translational, clinical and interdisciplinary research in cancer biology, diagnosis, treatment, outcome, supportive care, epidemiology and health disparities. Wilke H, et al. While a Korean study with a small sample size (n=6) once reported a 100% response rate in EBV-positive advanced GC [80], several other studies did not demonstrate a high response rate [81,82,83]. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide, This PDF is available to Subscribers Only. 0.481. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary results from phase 3 SPOTLIGHT study. Arch Surg. For example, patients with melanoma, which used to be considered a deadly disease, have much better prospects thanks to the breakthroughs in targeted and immune-based therapies. Wei J, et al. Gastric cancer (GC) is one of the most common malignancies worldwide. Current cancer incidence, mortality, and survival statistics Information on cancer symptoms, risk factors, early detection, and treatment monarchE was a large, global, randomised study conducted in patients with high-risk, hormone receptor-positive, HER2-negative . 1993;7:113. J Clin Oncol. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. These findings highlight the significance of ctDNA as a biomarker for predicting patient outcomes following perioperative cancer treatment and surgical resection in patients with GC. Performing a simultaneous operation allowed the patient to undergo rehabilitation after the treatment of two diseases during one hospitalization and, in the shortest possible time, to proceed to the next stage of gastric cancer treatmentchemotherapy, thereby improving the prognosis of life expectancy. volume2,pages 245246 (2021)Cite this article. 2018;29(4):103748. 2017;18(3):35770. 1980;115:299. Cancer. Cancer Metastasis Rev. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer Internet Explorer). A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Cancer Reports is an international, peer-reviewed, open access journal publishing basic, translational, clinical and interdisciplinary research in cancer biology, diagnosis, treatment, outcome, supportive care, epidemiology and health disparities. All authors read and approved the final manuscript. Janjigian YY, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Google Scholar. Bang YJ, et al. Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Am J Surg. 2006;355(1):1120. Xu RH, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. In light of the progress made so far and the goals and challenges ahead, we are pleased to launch in this issue of Nature Cancer a Series on Cancer Therapy comprising specially commissioned Review, Perspective, News and Comment articles and a collection of relevant primary research articles published in Nature Cancer. Springer Nature. Taking into consideration the economic component, traditional vascular prostheses are much cheaper than their endovascular analogues, with similar efficiency. MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaTrial in progress. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. 2017;18(11):146782. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. CA Cancer J Clin. Lancet Oncol. Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics, and population projections from the US Census Bureau. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Kang YK, et al. EBV has been linked to CD8+ T cell infiltration and increased expression of PD-L1 and PD-L2 [11, 79], making it a potential biomarker for ICI treatment. Accepted manuscripts They can be cited using the author(s), article title, journal title, year of online publication, and DOI. 2021;32:S10445. Specifically, Shusuke et al. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Reports in Cancer and Treatment - Google Scholar Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. Cancer https://doi.org/10.1038/s43018-021-00181-0 (2021). Raj S, et al. Top 100 in Cancer. Szilagyi DE, Elliott JP, Berguer R. Coincidental malignancy and abdominal aortic aneurysm: problems of management. Cancer Commun (Lond). In the subgroup analysis of the KEYNOTE-061 study, the TMB status (10 or<10 mut/Mb) was associated with response rate, PFS, and OS in patients treated with pembrolizumab. All authors declare that they have no competing interests. In another 1630-patient cohort of ctDNA results, genomic alterations were correlated with clinicopathologic characteristics and outcomes and provided prognostic and predictive information [188]. Catenacci DVT, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Ann Oncol. 2002;21:3511-3526. Circulating tumor cell (CTC) exerts diagnostic and prognostic value in colorectal cancer (CRC) patients. 2017;2(4):27787. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. After the completion, the abdominal cavity was lavaged with antiseptic solutions, which was a prevention of bacterial contamination of the aortic graft and allowed safe operation on the aorta. HER-family ligands promote acquired resistance to trastuzumab in gastric cancer. RC48 was well tolerated and showed promising antitumor activity in patients with HER2-positive advanced GC in a phase I trial [136]. Favorite PDF Permissions Original Article Randomized study assessing the cardiopulmonary toxicities from postoperative conventional versus hypofractionated radiotherapy in locally advanced left breast carcinoma 2021;39(15_suppl):40104010. Sahin U, et al. Shen L, et al. Park SR, et al. Hecht JR, et al. 2023 May 12;12(5):710. doi: 10.3390/biology12050710. More recently, the phase II/III MAHOGANY trial has reported the efficacy of margetuximab plus anti-PD-1 antibody retifanlimab (Cohort A) for the first-line treatment of patients with G/GEJ adenocarcinoma, with an ORR and a DCR of 53% and 73% [123]. Gastric cancer treatment: recent progress and future perspectives, https://doi.org/10.1186/s13045-023-01451-3, http://creativecommons.org/licenses/by/4.0/, http://creativecommons.org/publicdomain/zero/1.0/. J Clin Oncol. 2015;33(3_suppl): TPS226. Google Scholar. The Million-Dollar Cancer Treatment: Who Will Pay? - WSJ Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. 2019;37(15):1296304. Lancet. Lee JY, et al. Article Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Shitara K, et al. It should also be noted that advances in sophisticated cancer therapeutics are sometimes associated with a high financial burden for patients, a pressing societal issue tied to the complexities of addressing the challenge of cancer3. Van Cutsem E, et al. Department of Faculty Surgery No 1, Federal State Autonomous Educational Institution of Higher Education I.M. Nat Med.
Bahria Heights Apartments For Rent,
Ga Electrical License Practice Test,
Articles J